Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
Healthcare
$27.74 +2.60%
+$0.88 today
- Market cap
- $4.83B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
52W Low $6.92High $43.73
Volume 1.68M
Average 2.15M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$333.36M
FY 2025 · Annual
Net Income
-$328.94M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.62M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 55.91M | 121.63M | 173.76M | 232.66M | 269.78M |
| Selling, General & Admin | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M |
| Operating Expenses | 75.55M | 147.84M | 208.13M | 275.94M | 328.74M |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| EBITDA | (72.13M) | (130.37M) | (188.82M) | (251.51M) | (321.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (75.55M) | (147.84M) | (208.13M) | (275.94M) | (333.36M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 467K | 3.99M | 13.08M | 18.09M | 14.69M |
| Interest Expense | 0 | 3.99M | 0 | 0 | 3.06M |
| Other Income / Expenses | 3.28M | 7.6M | 15.72M | 20.08M | 4.43M |
| Income Before Tax | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| EPS (Diluted) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| 38.73M | 58.74M | 79.66M | 110.46M | 160.98M | |
| 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
COGT Earnings Waterfall · TTM
NASDAQ:COGT · Revenue to Net Income
Key Ratios
EPS$-2.31
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-13.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$377.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.31, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 8-K | Current report | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 31, 2026 |
How much revenue does COGT generate?
Cogent Biosciences, Inc. (COGT) reported $0.00 of revenue in fiscal 2025.
Is COGT profitable?
Cogent Biosciences, Inc. (COGT) reported -$328.94M of net income.
Continue the stock analysis
Jump to another research area for this company.